Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Alternatives to animal experimentation for hormonal compounds research.
Penza M
,
Jeremic M
,
Montani C
,
Unkila M
,
Caimi L
,
Mazzoleni G
,
Di Lorenzo D
.
???displayArticle.abstract???
Alternatives to animal testing and the identification of reliable methods that may decrease the need for animals are currently the subject of intense investigation worldwide. Alternative testing procedures are particularly important for synthetic and natural chemicals that exert their biological actions through binding nuclear receptors, called nuclear receptors-interacting compounds (NR-ICs), for which research is increasingly emphasizing the limits of several models in the accurate estimation of the physiological consequences of exposure to these compounds. In particular, estrogen receptor interacting compounds (ER-ICs) have a great impact on human health from the therapeutic, nutritional, and toxicological point of view due to the highly permissive nature of the estrogen receptors towards a large number of natural and synthetic compounds. Similar to in vitro systems, recently generated animal models (e.g., animal models generated for the study of estrogen receptor ligands) may fulfill the 3R principles: refine, reduce, and replace. If used correctly, NR-regulated models, such as reporter mice, xenopus, or zebrafish, and models obtained by somatic gene transfer in reporter systems, combined with imaging technologies, may contribute to strongly decreasing the overall number of animals required for NR-IC testing and research. With these models, flexible and highly standardized parameters and reporter marker quantification can be obtained. Here, we highlight the need for the substitution of currently used testing models with more appropriate ones that can reproduce the features and reactivity of specific mammalian target tissue/organs. We consider the promotion of this advancement a research priority bearing scientific, economic, social, and ethical relevance.
Adlercreutz,
Lignans and human health.
2007, Pubmed
Adlercreutz,
Lignans and human health.
2007,
Pubmed
Arendt,
Prolactin drives estrogen receptor-alpha-dependent ductal expansion and synergizes with transforming growth factor-alpha to induce mammary tumors in males.
2008,
Pubmed
Barton,
Endocrine active compounds: from biology to dose response assessment.
1998,
Pubmed
Bertil,
Expression of oestrogen-related receptor alpha in human epidermis.
2008,
Pubmed
Biserni,
In vivo imaging reveals selective peroxisome proliferator activated receptor modulator activity of the synthetic ligand 3-(1-(4-chlorobenzyl)-3-t-butylthio-5-isopropylindol-2-yl)-2,2-dimethylpropanoic acid (MK-886).
2008,
Pubmed
Bonefeld-Jørgensen,
Endocrine-disrupting potential of bisphenol A, bisphenol A dimethacrylate, 4-n-nonylphenol, and 4-n-octylphenol in vitro: new data and a brief review.
2007,
Pubmed
Buck Louis,
Environmental factors and puberty timing: expert panel research needs.
2008,
Pubmed
Carvan,
Transgenic zebrafish as sentinels for aquatic pollution.
2000,
Pubmed
Charles,
In vitro models in endocrine disruptor screening.
2004,
Pubmed
Chaudhuri,
Nuclear receptors and female reproduction: a tale of 3 scientists, Jensen, Gustafsson, and O'Malley.
2008,
Pubmed
Chung,
A 5' element of the chicken beta-globin domain serves as an insulator in human erythroid cells and protects against position effect in Drosophila.
1993,
Pubmed
Ciana,
The ERE-luc reporter mouse.
2004,
Pubmed
Ciana,
Engineering of a mouse for the in vivo profiling of estrogen receptor activity.
2001,
Pubmed
Ciana,
A novel peroxisome proliferator-activated receptor responsive element-luciferase reporter mouse reveals gender specificity of peroxisome proliferator-activated receptor activity in liver.
2007,
Pubmed
Ciana,
The dynamics of estrogen receptor activity.
2006,
Pubmed
Ciana,
In vivo imaging of transcriptionally active estrogen receptors.
2003,
Pubmed
De Bosscher,
Minireview: latest perspectives on antiinflammatory actions of glucocorticoids.
2009,
Pubmed
Di Lorenzo,
Molecular imaging, an innovative methodology for whole-body profiling of endocrine disrupter action.
2008,
Pubmed
Di Lorenzo,
Isomer-specific activity of dichlorodyphenyltrichloroethane with estrogen receptor in adult and suckling estrogen reporter mice.
2002,
Pubmed
Dukes,
The menopause and the pharmaceutical industry.
1997,
Pubmed
Eldridge,
Atrazine interaction with estrogen expression systems.
2008,
Pubmed
Ellwood-Yen,
Transgenic mouse model for rapid pharmacodynamic evaluation of antiandrogens.
2006,
Pubmed
Fiévet,
Liver X receptor modulators: effects on lipid metabolism and potential use in the treatment of atherosclerosis.
2009,
Pubmed
Goldstein,
A pharmacological review of selective oestrogen receptor modulators.
2000,
Pubmed
Hsieh,
A luciferase transgenic mouse model: visualization of prostate development and its androgen responsiveness in live animals.
2005,
Pubmed
Jackman,
Isoflavones, equol and cardiovascular disease: pharmacological and therapeutic insights.
2007,
Pubmed
Jacobson-Dickman,
The influence of endocrine disruptors on pubertal timing.
2009,
Pubmed
Ke,
Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models.
1998,
Pubmed
Koehler,
Reflections on the discovery and significance of estrogen receptor beta.
2005,
Pubmed
Komm,
Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity.
2005,
Pubmed
Lemmen,
Tissue- and time-dependent estrogen receptor activation in estrogen reporter mice.
2004,
Pubmed
Maggi,
Reporter mice and drug discovery and development.
2005,
Pubmed
Marchetti,
Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
2004,
Pubmed
May,
Transcriptional control of SV40 T-antigen expression allows a complete reversion of immortalization.
2004,
Pubmed
Mazzoleni,
Modelling tissues in 3D: the next future of pharmaco-toxicology and food research?
2009,
Pubmed
Nordlund,
Hormones for life? Behind the rise and fall of a hormone remedy (Gonadex) against sterility in the Swedish welfare state.
2007,
Pubmed
O'Malley,
The Year in Basic Science: nuclear receptors and coregulators.
2008,
Pubmed
O'Malley,
Coactivators and corepressors: what's in a name?
2008,
Pubmed
Ondrey,
Peroxisome proliferator-activated receptor gamma pathway targeting in carcinogenesis: implications for chemoprevention.
2009,
Pubmed
Ornstein,
Hormonal contraception in adolescents: special considerations.
2006,
Pubmed
Ottobrini,
Molecular imaging: a new way to study molecular processes in vivo.
2006,
Pubmed
Qu,
Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats.
2000,
Pubmed
Schweppe,
Endometriosis market research: an overview of findings in Europe and the United States.
2005,
Pubmed
Smith,
Coregulator function: a key to understanding tissue specificity of selective receptor modulators.
2004,
Pubmed
Song,
Soy isoflavones as safe functional ingredients.
2007,
Pubmed
Stell,
Multimodality imaging: novel pharmacological applications of reporter systems.
2007,
Pubmed
Stief,
A nuclear DNA attachment element mediates elevated and position-independent gene activity.
1989,
Pubmed
Suzuki,
Dietary lignans and postmenopausal breast cancer risk by oestrogen receptor status: a prospective cohort study of Swedish women.
2008,
Pubmed
Traupe,
Distinct roles of estrogen receptors alpha and beta mediating acute vasodilation of epicardial coronary arteries.
2007,
Pubmed
Trudeau,
Assessment of estrogenic endocrine-disrupting chemical actions in the brain using in vivo somatic gene transfer.
2005,
Pubmed
,
Xenbase
Tsukui,
[Role of estrogen signaling in male bone].
2006,
Pubmed
Van den Belt,
Comparative study on the in vitro/in vivo estrogenic potencies of 17beta-estradiol, estrone, 17alpha-ethynylestradiol and nonylphenol.
2004,
Pubmed
Vandenberg,
Bisphenol-A and the great divide: a review of controversies in the field of endocrine disruption.
2009,
Pubmed
Villa,
Target-specific action of organochlorine compounds in reproductive and nonreproductive tissues of estrogen-reporter male mice.
2004,
Pubmed
Wilson,
Position effects on eukaryotic gene expression.
1990,
Pubmed
Yang,
Expression of oestrogen receptor-alpha and oestrogen receptor-beta in prostate cancer.
2007,
Pubmed
Zollner,
Nuclear receptors as therapeutic targets in cholestatic liver diseases.
2009,
Pubmed
de Ronde,
The importance of oestrogens in males.
2003,
Pubmed